Aardvark Therapeutics Business Summary

Aardvark Therapeutics, Inc. (AARD) is a clinical-stage biopharmaceutical company that operates on a research-and-development-driven business model, primarily targeting future revenue through the commercialization, licensing, and milestone-based partnerships of its proprietary small-molecule pipeline. The company’s primary business segments are focused on metabolic and inflammatory diseases, with a lead clinical program, ARD-101, currently in Phase 3 trials for hyperphagia in Prader-Willi Syndrome (PWS) and a secondary focus on obesity through its ARD-201 candidate. Aardvark differentiates itself by utilizing gut-restricted agonists of Bitter Taste Receptors (TAS2Rs) to modulate innate homeostatic pathways and the gut-brain axis. Within the competitive landscape, Aardvark contends with metabolic-focused firms such as Altimmune, 89bio, Viking Therapeutics, and MoonLake Immunotherapeutics, positioning itself as a specialized, small-cap innovator in the hunger-regulation and metabolic-niche market. The company was founded by Tien-Li Lee, M.D., who serves as the current Chief Executive Officer and brings a deep pedigree in clinical drug development. The executive leadership team includes Nelson Sun, who serves as both Chief Financial Officer and Chief Operating Officer (appointed February 2026), and Timothy Kieffer, Ph.D., the Chief Technology Officer and Head of R&D, recognized for his extensive research background in metabolic health. The team was further strengthened in early 2026 by the appointment of Derrick C. Li as Chief Business Officer, a seasoned executive with over 20 years of experience in biopharmaceutical strategy and investment banking. Aardvark is a Nasdaq-listed entity (AARD) backed by notable institutional investors including Vickers Venture Partners, and it maintains a robust cash position following its February 2025 IPO to fund operations through 2027.